|
1
|
Khatri VP, Petrelli NJ and Belghiti J:
Extending the frontiers of surgical therapy for hepatic colorectal
metastases: Is there a limit? J Clin Oncol. 23:8490–8499. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aranda E, Abad A, Carrato A, Cervantes A,
García-Foncillas J, García Alfonso P, García Carbonero R, Gómez
España A, Tabernero JM and Díaz-Rubio E: Treatment recommendations
for metastatic colorectal cancer. Clin Transl Oncol. 13:162–178.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giantonio BJ, Levy DE, O'dwyer PJ, Meropol
NJ, Catalano PJ and Benson AB III; Eastern Cooperative Oncology
Group, : A phase II study of high-dose bevacizumab in combination
with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for
advanced colorectal cancer: Results from the eastern cooperative
oncology group study E2200. Ann Oncol. 17:1399–1403. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rees M, Tekkis PP, Welsh FK, O'Rourke T
and John TG: Evaluation of long-term survival after hepatic
resection for metastatic colorectal cancer: A multifactorial model
of 929 patients. Ann Surg. 247:125–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pawlik TM, Scoggins CR, Zorzi D, Abdalla
EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, et
al: Effect of surgical margin status on survival and site of
recurrence after hepatic resection for colorectal metastases. Ann
Surg. 241:715–724. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nordlinger B, Guiguet M, Vaillant JC,
Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical
resection of colorectal carcinoma metastases to the liver. A
prognostic scoring system to improve case selection, based on 1568
patients. Association Française de Chirurgie. Cancer. 77:1254–1262.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cirocchi R, Trastulli S, Boselli C,
Montedori A, Cavaliere D, Parisi A, Noya G and Abraha I:
Radiofrequency ablation in the treatment of liver metastases from
colorectal cancer. Cochrane Database Syst Rev. 13:CD0063172012.
|
|
9
|
Minami Y and Kudo M: Radiofrequency
ablation of liver metastases from colorectal cancer: A literature
review. Gut Liver. 7:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
National Comprehensive Cancer Network, .
Guidelines version 2.2016 updates colon cancer. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdfJune
12–2016
|
|
11
|
National Comprehensive Cancer Network:
Guidelines version 2.2016 rectal cancer. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdfJune
12–2016
|
|
12
|
Rieber J, Streblow J, Uhlmann L, Flentje
M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien
R, et al: Stereotactic body radiotherapy (SBRT) for medically
inoperable lung metastases-A pooled analysis of the German working
group ‘stereotactic radiotherapy’. Lung Cancer. 97:51–58. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanna GG and Landau D: Stereotactic body
radiotherapy for oligometastatic disease. Clin Oncol (R Coll
Radiol). 27:290–297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takeda A, Sanuki N and Kunieda E: Role of
stereotactic body radiotherapy for oligometastasis from colorectal
cancer. World J Gastroenterol. 20:4220–4229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Binkley MS, Trakul N, Jacobs LR, von Eyben
R, Le QT, Maxim PG, Loo BW Jr, Shultz DB and Diehn M: Colorectal
histology is associated with an increased risk of local failure in
lung metastases treated with stereotactic ablative radiation
therapy. Int J Radiat Oncol Biol Phys. 92:1044–1052. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takeda A, Sanuki N, Tsurugai Y, Oku Y and
Aoki Y: Stereotactic body radiotherapy for patients with
oligometastases from colorectal cancer: Risk-adapted dose
prescription with a maximum dose of 83–100 Gy in five fractions. J
Radiat Res. 57:400–405. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmed KA, Caudell JJ, El-Haddad G,
Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA,
Frakes JM, et al: Radiosensitivity differences between liver
metastases based on primary histology suggest implications for
clinical outcomes after stereotactic body radiation therapy. Int J
Radiat Oncol Biol Phys. 95:1399–1404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vautravers-Dewas C, Dewas S, Bonodeau F,
Adenis A, Lacornerie T, Penel N, Lartigau E and Mirabel X:
Image-guided robotic stereotactic body radiation therapy for liver
metastases: Is there a dose response relationship? Int J Radiat
Oncol Biol Phys. 81:e39–e47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wulf J, Guckenberger M, Haedinger U,
Oppitz U, Mueller G, Baier K and Flentje M: Stereotactic
radiotherapy of primary liver cancer and hepatic metastases. Acta
Oncol. 45:838–847. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamashita H, Onishi H, Matsumoto Y,
Murakami N, Matsuo Y, Nomiya T and Nakagawa K; Japanese
Radiological Society multi-institutional SBRT study group
(JRS-SBRTSG), : Local effect of stereotactic body radiotherapy for
primary and metastatic liver tumors in 130 Japanese patients.
Radiat Oncol. 9:1122014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rusthoven KE, Kavanagh BD, Cardenes H,
Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin
W, Kane M, et al: Multi-institutional phase I/II trial of
stereotactic body radiation therapy for liver metastases. J Clin
Oncol. 27:1572–1578. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Engels B, Gevaert T, Everaert H, De
Coninck P, Sermeus A, Christian N, Storme G, Verellen D and De
Ridder M: Phase II study of helical tomotherapy in the
multidisciplinary treatment of oligometastatic colorectal cancer.
Radiat Oncol. 7:342012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Doi H, Shiomi H, Masai N, Tatsumi D, Igura
T, Imai Y and Oh RJ: Threshold doses and prediction of visually
apparent liver dysfunction after stereotactic body radiation
therapy in cirrhotic and normal livers using magnetic resonance
imaging. J Radiat Res. 57:294–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Common terminology criteria for adverse
events version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfApril
3–2017
|
|
25
|
Folprecht G, Grothey A, Alberts S, Raab HR
and Köhne CH: Neoadjuvant treatment of unresectable colorectal
liver metastases: Correlation between tumour response and resection
rates. Ann Oncol. 16:1311–1319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brown JM, Diehn M and Loo BW Jr:
Stereotactic ablative radiotherapy should be combined with a
hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys.
78:323–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Loupakis F, Yang D, Yau L, Feng S,
Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ,
et al: Primary tumor location as a prognostic factor in metastatic
colorectal cancer. J Natl Cancer Inst. 107:pii:dju4272015.
View Article : Google Scholar
|
|
28
|
Tran B, Kopetz S, Tie J, Gibbs P, Jiang
ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O and Desai J: Impact of
BRAF mutation and microsatellite instability on the pattern of
metastatic spread and prognosis in metastatic colorectal cancer.
Cancer. 117:4623–4632. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Distler P and Holt PR: Are right- and
left-sided colon neoplasms distinct tumors? Dig Dis. 15:302–311.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Iacopetta B: Are there two sides to
colorectal cancer? Int J Cancer. 101:403–408. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hutchins G, Southward K, Handley K, Magill
L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M,
Kerr D, et al: Value of mismatch repair, KRAS, and BRAF mutations
in predicting recurrence and benefits from chemotherapy in
colorectal cancer. J Clin Oncol. 29:1261–1270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Loupakis F, Ruzzo A, Cremolini C, Vincenzi
B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E,
et al: KRAS codon 61, 146 and BRAF mutations predict resistance to
cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type
metastatic colorectal cancer. Br J Cancer. 101:715–721. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ayiomamitis GD, Notas G, Zaravinos A,
Zizi-Sermpetzoglou A, Georgiadou M, Sfakianaki O and Kouroumallis
E: Differences in telomerase activity between colon and rectal
cancer. Can J Surg. 57:199–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Spitz FR, Giacco GG, Hess K, Larry L, Rich
TA, Janjan N, Cleary KR and Skibber JM: p53 immunohistochemical
staining predicts residual disease after chemoradiation in patients
with high-risk rectal cancer. Clin Cancer Res. 3:1685–1690.
1997.PubMed/NCBI
|
|
35
|
Hall EJ and Giaccia AJ: Radiobiology for
the radiologist. 7th. Philadelphia: Lippincott Williams &
Wilkins; 2011
|
|
36
|
Doi H, Oh RJ, Miura H, Masai N, Shiomi H
and Inoue T: Outcomes and toxicity of radiotherapy for refractory
bone and soft tissue sarcomas. Mol Clin Oncol. 4:83–88.
2016.PubMed/NCBI
|
|
37
|
Miura H, Masai N, Oh RJ, Shiomi H, Sasaki
J and Inoue T: Approach to dose definition to the gross tumor
volume for lung cancer with respiratory tumor motion. J Radiat Res.
54:140–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Thames HD and Suit HD: Tumor
radioresponsiveness versus fractionation sensitivity. Int J Radiat
Oncol Biol Phys. 12:687–691. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park HJ, Griffin RJ, Hui S, Levitt SH and
Song CW: Radiation-induced vascular damage in tumors: Implications
of vascular damage in ablative hypofractionated radiotherapy (SBRT
and SRS). Radiat Res. 177:311–327. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brown JM, Carlson DJ and Brenner DJ: The
tumor radiobiology of SRS and SBRT: Are more than the 5 Rs
involved? Int J Radiat Oncol Biol Phys. 88:254–262. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Qian Y, Zeng ZC, Ji Y and Xiao YP:
Microinvasion of liver metastases from colorectal cancer:
Predictive factors and application for determining clinical target
volume. Radiat Oncol. 10:1252015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Welter S, Theeqarten D, Trarbach T,
Maletzki F, Stamatis G and Tötsch M: Safety distance in the
resection of colorectal lung metastases: A prospective evaluation
of satellite tumor cells with immunohistochemistry. J Thorac
Cardiovasc Surg. 141:1218–1222. 2011. View Article : Google Scholar : PubMed/NCBI
|
